© Copyright 2008 by the Society for Neuro-Oncology
Received February 3, 2008
Accepted April 29, 2008
Presence of 1q gain and absence of 7p gain are new predictors of local or metatastic relapse in localized resectable neuroblastoma
Annalisa Pezzolo 1*,
Elena Rossi 2,
Stefania Gimelli 2,
Federica Parodi 3,
Francesca Negri 4,
Massimo Conte 5,
Angela Pistorio 6,
Angela Sementa 4,
Vito Pistoia 3,
Orsetta Zuffardi 2,
Claudio Gambini 4
1 Department of Oncology, IRCCS G. Gaslini Hospital, Largo G. Gaslini, 5, 16147 Genova-Quarto, Italy
2 IRCCS G. Gaslini Hospital, Genoa, Italy; Medical Genetics Department, University of Pavia, Pavia, Italy
3 Department of Oncology, IRCCS G. Gaslini Hospital, Genoa, Italy; Medical Genetics Department, University of Pavia, Pavia, Italy
4 Department of Pathology, IRCCS G. Gaslini Hospital, Genoa, Italy; Medical Genetics Department, University of Pavia, Pavia, Italy
5 Hematology-Oncology Unit, IRCCS G. Gaslini Hospital, Genoa, Italy; Medical Genetics Department, University of Pavia, Pavia, Italy
6 Epidemiology and Biostatistics Unit, IRCCS G. Gaslini Hospital, Genoa, Italy; Medical Genetics Department, University of Pavia, Pavia, Italy
* To whom correspondence should be addressed. E-mail: annalisapezzolo{at}ospedale-gaslini.ge.it.
 |
Abstract |
|---|
We have addressed the search of novel genetic prognostic markers in a selected cohort of patients with localized resectable neuroblastoma (NB), stroma poor, who underwent relapse or progression (group 1) or complete remission (group 2) over a minimum follow-up of 32 months from diagnosis. Twenty three Italian patients with localized resectable NB (stages 1 and 2) diagnosed from 1994 to 2005 were studied. All patients received surgical treatment. Chemotherapy was administered only to the three stage 2 patients who had MYCN amplified tumors. High-resolution array-comparative genomic hybridization (CGH) DNA copy-number analysis technology was used in order to identify novel prognostic markers. Chromosome 1p36.22p36.32 loss and 1q22qter gain, detected almost exclusively in group 1 patients, were significantly associated with poor event-free survival (EFS) (P = 0.0024 and P = 0.024, respectively). In contrast, patients with 7p11.2p22 gain, who belonged predominantly to group 2, had a significantly better EFS (P = 0.015). The frequency of 17q gain or 3 and 11q losses did not differ significantly in group 1 vs group 2 NBs. The sensitive technique used allowed us to define the smallest region of 1p deletion. In conclusion, 1q22qter gain and 7p11.2p22 gain might represent new prognostic markers in localized resectable NB, but the small study size and the retrospective nature of the findings warrant further validation of the results obtained in larger studies.
Key Words:
1q gain, 7p gain, array-CGH, localized resectable neuroblastoma, prognostic markers
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
